Revolution Medicines’ buyout price soars after pancreatic cancer winnews2026-04-17T13:20:06+00:00April 17th, 2026|Endpoints News|
China dominates big licensing deals as M&A starts 2026 with a bangnews2026-04-15T13:00:51+00:00April 15th, 2026|Endpoints News|
Eli Lilly to pay up to $300M for cancer biotech CrossBridge Bionews2026-04-14T12:00:51+00:00April 14th, 2026|Endpoints News|
Regeneron wades into radiopharma through $40M upfront deal with Telixnews2026-04-13T14:51:29+00:00April 13th, 2026|Endpoints News|
Post-Hoc Live: Biopharma M&A is back, with Barclays’ Emily Fieldnews2026-04-09T18:12:49+00:00April 9th, 2026|Endpoints News|
Roche dips into DACs with existing partner C4 Therapeutics for $20M upfrontnews2026-04-09T14:17:59+00:00April 9th, 2026|Endpoints News|
Gilead takes another big swing at expanding beyond HIVnews2026-04-08T15:10:43+00:00April 8th, 2026|Endpoints News|
Inside the Talkspace-Universal Health Services dealnews2026-04-08T14:23:54+00:00April 8th, 2026|Endpoints News|
Did Eli Lilly just strike another gold mine?news2026-04-07T19:29:41+00:00April 7th, 2026|Endpoints News|
